Schering-Plough is committed to advancing the science and treatment of hepatitis C, both in terms of its internal research and development programs, and by collaborating with other companies. In addition, Schering-Plough is committed to supporting hepatitis C patients through its leading disease awareness, education and service programs.
Approximately 170 million people are chronically infected with hepatitis C worldwide and there are approximately 3 to 4 million new HCV infections each year on a global basis. Chronic hepatitis C can cause cirrhosis, liver failure and liver cancer. About half of all cases of primary liver cancer in the developed world are caused by hepatitis C, and hepatitis C related liver disease is now the leading cause for liver transplants. Most people who develop chronic hepatitis C infection are not aware that they have the disease.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
In addition, OraSure sells products for the cryosurgical removal of
common and pla
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved